Connect with us

Science

5 Top Biotech Stocks To Watch In January 2022

Could these biotech stocks be poised for gains in 2022?
The post 5 Top Biotech Stocks To Watch In January 2022 appeared first on Stock Market News, Quotes, Charts and Financial Information | StockMarket.com.

Published

on

5 Biotech Stocks For Your Mid-January 2022 Watchlist

Biotech stocks have often been a popular theme in the stock market. Even without the catalyst from the ongoing pandemic, the industry is one that many investors keep a close tab on. Now, why is that so? For starters, biotech is well-known for being a high-risk, high-reward industry. With multiple phases of trials and billions of dollars in capital at stake, the sky is often the limit for biotech stocks. Look no further than Moderna (NASDAQ: MRNA) which has grown by more than ten-fold since the onset of the pandemic. And that is thanks to the company being one of the pioneers of the coronavirus vaccine. 

That said, most companies may not get a fairy tale ending like Moderna and would likely take years to have a breakthrough, if at all. So, investors should understand what they’re looking for and the risks as well. In the current climate, the coronavirus pandemic is still a concern after two dreadful years. For instance, GlaxoSmithKline (NYSE: GSK) and Vir Biotechnology (NASDAQ: VIR) announced that they will be supplying the U.S. government an additional 600,000 doses of their monoclonal antibody, sotrovimab. With that in mind, would you put up a list of top biotech stocks to watch the stock market today?

Best Biotech Stocks To Watch In January 2022

Adagio Therapeutics

First up, we will be looking at Adagio. For those unaware, this is a clinical-stage biopharmaceutical company that specializes in antibody-based solutions for infectious diseases that have pandemic potential. Now, its primary focus is on the virus SARS-CoV-2, its variants, and the disease caused by the virus. Its lead product candidate, ADG20, has been gaining plenty of traction in the stock market lately.

ADGI stock chart

For starters, the company summarized recent findings reported in three separate publications that show the drug has neutralization activity against the Omicron variant. There are also outlines concerning initiatives to address the current and future variants of concerns.

Furthermore, Adagio is evaluating ADG20 in its global Phase 2/3 clinical trials for both the prevention and treatment of COVID-19. Should the drug receive authorization soon, it would be a huge boost for Adagio. All things considered, would you be jumping on the ADGI stock bandwagon?

[Read More] Best Lithium Battery Stocks To Buy Now? 4 To Know

Pacific Biosciences

Following that, we will be looking at Pacific Biosciences of California (PACB). In detail, the company specializes in sequencing systems to help scientists resolve genetically complex problems. As of now, the company has developed its Single Molecule, Real-Time (SMRT) technology. This technology enables single-molecule, real-time detection of nucleic acid sequences and addresses many of the limitations of previous sequencing technologies. 

Earlier this week, PACB along with Berry Genomics announced a collaboration to provide PACB’s long-read sequencing technology to the Chinese clinical market. Under the agreement, PACB will develop its first long-read desktop sequencing platform with funding and guidance from Berry. So, once the product is ready, Berry will purchase at least 50 systems for use and sale in China. Keeping this in mind, would you consider adding PACB stock to your watchlist?

Vertex Pharmaceuticals

Another top biotech company you should note is Vertex Pharmaceuticals. It is a company that focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF). Besides that, it is also in the midst of advancing its research and development programs in other indications. Currently, the company has several approved medicines that treat the underlying cause of CF. This includes KAFTRIO, SYMDEKO, ORKAMBI, and KALYDECO. 

best pharma stocks to watch (VRTX stock)

Recently, there are reasons for optimism among VRTX stock investors. It announced on Tuesday that the European Commission has approved the label extension of KAFTRIO in a combination regimen with ivacaftor. This indication is for patients aged 6 through 11 years old who have at least one F508del mutation in the CF transmembrane conductance regulator gene.

Hence, this would provide more treatment options for physicians to treat this devastating disease in early life. Given this exciting development, would you consider VRTX stock a top biotech stock to watch right now?

[Read More] Best Monthly Dividend Stocks To Buy Now? 5 For Your List

BioNTech

BioNTech is a Germany-based clinical-stage biotechnology company. Essentially, it focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. In addition, the company also develops a broad product pipeline using different scientific approaches and technology platforms.

top biotech stocks to watch (BNTX stock)

Well, BNTX stock is yet another vaccine company that has benefited greatly from the pandemic. More than doubling its value over the past year, some still see it as one of the top picks in the biotech industry. 

Last week, the company and InstaDeep Ltd announced the development of a new computational method. It can analyze worldwide available sequencing data and predicts high-risk variants of SARS-CoV-2. By combining structural modeling of the viral Spike protein and AI algorithms, it can flag potentially high-risk variants entered into SARS-CoV-2 sequence data repositories within less than a day. In a pandemic where a new variant emerges ever so often, this new development would be a welcome addition. With that said, would you consider investing in the future of BNTX stock?

[Read More] Best Artificial Intelligence Stocks To Buy Right Now? 5 To Watch

Novavax

Last but not least, we have the clinical-stage biotech company, Novavax. Put simply, the company specializes in recombinant nanoparticle vaccines and adjuvants. By leveraging its recombinant nanoparticle vaccine technology, it produces vaccine candidates to respond to both known and newly emerging diseases.

best biotech stocks (NVAX stock)

With Omicron running wild right now, NVAX stock is often under the limelight among investors. Despite waiting for its vaccine to be authorized in the U.S., it already made its mark in three major markets globally. The company CEO, Stanley Erck, claims that the company is “going to make a significant impact on this Covid pandemic”. 

Yesterday, Novavax and SK Bioscience announced that South Korea’s Ministry of Food and Drug Safety has approved a Biologics License Application (BLA) from SK Bioscience for Nuvaxovid COVID-19 Vaccine. The vaccine is indicated for active immunization in individuals 18 years of age and older to prevent COVID-19. Slowly, but surely, the company’s coronavirus vaccine is seeing adoption in more countries around the world. With that said, should you be eyeing NVAX stock?


If you enjoyed this article and you’re interested in learning how to trade so you can have the best chance to profit consistently then you need to checkout this YouTube channel. CLICK HERE RIGHT NOW!


The post 5 Top Biotech Stocks To Watch In January 2022 appeared first on Stock Market News, Quotes, Charts and Financial Information | StockMarket.com.

Read More

Continue Reading

Spread & Containment

Lactation Lab receives FDA Breakthrough Device designation for breast-milk-testing device that allows mothers to test for key nutritional elements in their milk

Los Angeles, May 25, 2022 –Lactation Lab, which offers the most scientifically advanced breast milk testing available, has announced today that the…

Published

on

Los Angeles, May 25, 2022 –Lactation Lab, which offers the most scientifically advanced breast milk testing available, has announced today that the U.S. Food and Drug Administration (FDA), has granted the company Breakthrough Device designation for its latest device Emily’s Care Nourish Test System that tests and provides a nutritional analysis of breast milk. 

Credit: Dr. Stephanie Canale

Los Angeles, May 25, 2022 –Lactation Lab, which offers the most scientifically advanced breast milk testing available, has announced today that the U.S. Food and Drug Administration (FDA), has granted the company Breakthrough Device designation for its latest device Emily’s Care Nourish Test System that tests and provides a nutritional analysis of breast milk. 

This first-of-its-kind breast-milk (point of care)-test allows mothers to test for key macronutrients (fat, protein, carbohydrates and adjust their nutritional intake accordingly. The test was developed for use in the NICU, hospital clinics, milk banks and home use. 

“The FDA Breakthrough Device designation for Emily’s Care Test System is a critical step in serving the most vulnerable infant population,” says Dr. Stephanie Canale, CEO of Lactation Lab. “Research in the past five years demonstrates how important key nutrients are for babies in the first five weeks of life. Nutrition is the only modifiable factor for preterm babies, and our Emily’s Care device provides potentially life-saving data, especially for those at risk of life-threatening conditions.”

The FDA Breakthrough Device designation will expedite regulatory review of Emily’s Care to provide patients and health care providers with quicker access. The designation is only awarded to breakthrough technologies that have the potential to provide effective treatment and diagnosis for life-threatening or irreversible debilitating diseases or conditions.

Founded in 2017 by CEO Dr. Stephanie Canale, Lactation Lab’s proprietary tests were developed by a team of practicing physicians, Ph.D. chemists and toxicologists. The startup company is housed at the Magnify Incubator at the California NanoSystems Institute at UCLA, which provides access to one of the most advanced research labs in the world. 

Lactation Lab is pioneering academic research in breast milk composition, also publishing findings in several prominent scientific journals, including Breastfeeding Medicine and Clinical Lactation.

Canale, a physician formerly at UCLA whose practice largely consisted of new mothers and babies, started Lactation Lab to provide parents with scientific and evidence-based insights, resources, and guidance. As a mom with an infant diagnosed with “failure to thrive,” also known as growth faltering. Canale wondered why there was no way to know what was in her own breast milk. 

“The time is now to empower moms with the kind of information and peace of mind I needed during my own breastfeeding journey. During the Covid-19 pandemic, amid the anxiety of leaving the home and going to doctor’s visits, we decided to bring Emily’s Care directly to mothers and take the guesswork out of breastfeeding,” said Canale. 

Lactation Lab’s breast-milk-test surpasses the creamatocrit breast milk test first developed in 1978. This rudimentary test is still widely used in hospitals, NICUs and support centers. Lactation Lab’s Emily’s aims to replace the existing test with Emily’s Care, which provides more accurate data than infra-red human milk analyzers. The company also just launched Emily’s Care infant supplement, which is the first infant supplement to receive Clean Label Project Certification and will support breastfeeding babies.

“We would like to continue advancements in women’s health to remove the current stigma around postpartum care and breastfeeding,” said Canale. “The data supports objective, evidence-based decision-making not only for hospitals and NICUs, but also for mothers at home. These are revolutionary steps to improve the standard of care surrounding breast milk for mom and baby.” 

Currently in the seed round of funding. Those interested in investing in Lactation Lab may reach out to scanale@lactationlab.com. To learn more, visit lactationlab.com and join the conversation @lactationlab.

About Lactation Lab

Founded by CEO Stephanie Canale, a doctor and mother of two, Lactation Lab is a first-of-its-kind breast-milk-testing kit. Lactation Lab analyzes your breast milk for basic nutritional content like calories and protein, as well as vitamins, fatty acids, and environmental toxins. Results are delivered in a user-friendly report that reads like a food label. Lactation Lab explains how results affect children, offers suggestions for enhancing the quality of milk, and offers personal consultation. Other products include mastitis screening test strips and the company will soon be launching a Clean Label certified infant supplement. Learn more at www.lactationlab.com.

About the FDA Breakthrough Device Program

The FDA Breakthrough Device program enables expedited regulatory assessment of novel technologies with the potential to provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. The goal of the Breakthrough Devices Program is to provide patients and health care providers with timely access to these medical devices by speeding up their development, assessment, and review, while preserving the statutory standards for premarket approval, 510(k) clearance, and De Novo marketing authorization, consistent with the Agency’s mission to protect and promote public health.

About Magnify Incubator at the California NanoSystems Institute at UCLA 

Centrally located at UCLA’s Court of Sciences, Magnify strives to enhance the vibrant culture of entrepreneurship at UCLA and the broader Los Angeles region. Magnify was built with one goal in mind: to help startups succeed by vastly accelerating their access to facilities while increasing their capital efficiency and market opportunities.

Related Links

www.lactationlab.com
magnify.cnsi.ucla.edu

Learn more about Lactation Lab from CEO Dr. Stephanie Canale
https://www.youtube.com/watch?v=3t4Q1OX05lg


Read More

Continue Reading

Spread & Containment

Hertz Foundation announces 2022 Hertz fellows

The Fannie and John Hertz Foundation today announced the recipients of the prestigious 2022 Hertz Fellowships in applied science, mathematics and engineering….

Published

on

The Fannie and John Hertz Foundation today announced the recipients of the prestigious 2022 Hertz Fellowships in applied science, mathematics and engineering.

Credit: Fannie and John Hertz Foundation

The Fannie and John Hertz Foundation today announced the recipients of the prestigious 2022 Hertz Fellowships in applied science, mathematics and engineering.

This year’s fellowships will fund 13 remarkable doctoral students who demonstrate extraordinary potential to become foremost leaders in their fields and tackle the most significant challenges facing the nation and the world. The fellowship will directly support researchers interested in defending the nation’s digital infrastructure against cyberthreats, developing more efficient electronics that can help reduce dependence on fossil fuels, and creating biomedical devices to aid rehabilitation and cancer diagnostics.

“To remain a global leader in science and technology, our nation requires enterprising minds capable of inventing creative solutions to real problems,” said Robbee Baker Kosak, president of the Hertz Foundation. “We’re thrilled to be able to support these promising innovators and fuel their research at such a pivotal time in their careers.”

Since 1963, the Hertz Foundation has granted fellowships empowering the nation’s most promising young minds in science and technology. Hertz Fellows receive five years of funding, valued up to $250,000, which offers flexibility from the traditional constraints of graduate training and the independence needed to pursue research that best advances our security and economic vitality.

In addition to receiving financial support, Hertz Fellows join a multigenerational, intellectual community of peers, which offers a unique engine for professional development and collaboration. Hertz Fellows have access to lifelong programming, such as mentoring, events, and networking, which has led them to form research collaborations, commercialize technology, and create and invest in early-stage companies together, among other opportunities.

Among the past recipients of the Hertz Fellowship are Nobel laureate John Mather, a NASA astrophysicist and project scientist for the James Webb Space Telescope; Kim Budil, director of Lawrence Livermore National Laboratory; Nathan Myhrvold, founder and CEO of Intellectual Ventures, founding director of Microsoft Research, and former chief technology officer at Microsoft; Kathleen Fisher, deputy office director for the Defense Advanced Research Projects Agency Information Innovation Office; and neuroscientist Ed Boyden of the Massachusetts Institute of Technology, who is developing optogenetic technologies to understand and treat brain conditions such as Parkinson’s disease. 

The Hertz Foundation is dedicated to expanding and accelerating the U.S. pipeline of scientific and technical leadership. Through a rigorous and time-tested selection process, led by Hertz Fellow Philip Welkhoff, director of the malaria program at the Bill & Melinda Gates Foundation, the fellowship selection committee sought out candidates demonstrating deep, interconnecting knowledge and the extraordinary creativity necessary to tackle problems that others can’t solve.

“John Hertz’s vision was that as new challenges arise, a vibrant and innovative cadre of researchers in the applied sciences was essential for facing and overcoming them,” said Welkhoff. “This cohort of Hertz Fellows embodies these values in so many unique and individual ways. I am delighted to welcome them into the Hertz community and to see what they achieve in the decades ahead.”

The 2022 class joins a community of fellows comprising some of the nation’s most noted science and technology leaders, whose transformative research and innovation impact our lives every day. Hertz Fellows have increased the accessibility of ultrasounds with the invention of a low-cost handheld device and helped prove the big-bang theory of the universe. They are using machine learning to investigate disparities in COVID-19 testing and develop collaborative research tools. They have saved lives with a simple test that reveals fake pharmaceuticals, are influencing companies to institute environmentally sound practices, and are developing aircraft powered by hydrogen fuel cells for energy-efficient, lower-cost transportation.

Over the foundation’s 59-year history of awarding fellowships, more than 1,200 Hertz Fellows have established a remarkable track record of accomplishments. Their ranks include two Nobel laureates; recipients of eight Breakthrough Prizes and three MacArthur Foundation “genius awards”; and winners of the Turing Award, the Fields Medal, the National Medal of Technology and the National Medal of Science. In addition, 48 are members of the National Academies of Sciences, Engineering and Medicine, and 32 are fellows of the American Association for the Advancement of Science. Hertz Fellows hold over 3,000 patents, have founded more than 375 companies, and have created hundreds of thousands of science and technology jobs.

Introducing the 2022 Hertz Fellows

Fellows are listed with their graduate university affiliations and fields of interest.

Roderick Bayliss III
University of California, Berkeley
Power Electronics

Roderick Bayliss wants to design more efficient and power-dense electronics, a step toward reducing the world’s dependence on fossil fuels. Currently a graduate student at the University of California, Berkeley, Bayliss has already carried out work developing novel types of power converters — devices that change the current, voltage or frequency of electrical energy — and inductors, which store energy. He received both his bachelor’s degree and his master’s degree in electrical engineering from MIT.

Nikhil Bhattasali
New York University
Neuroscience, Artificial Intelligence

Nikhil Bhattasali is interested in understanding biological intelligence to build better artificial intelligence. Inspired by animal nervous systems, he assembles computational models that can control embodied agents and robots. Currently a NeuroAI Scholar at Cold Spring Harbor Laboratory, Bhattasali conducts highly interdisciplinary research combining machine learning, systems neuroscience and computer science. Bhattasali received both his bachelor’s degree in symbolic systems and his master’s degree in computer science from Stanford University. He will be joining the doctorate program in computer science at New York University in fall 2022. 

Alexander Cohen
Massachusetts Institute of Technology
Mathematics

Alexander Cohen studies how waves interfere with each other — a topic of mathematics that has far-reaching implications across computer science, physics and number theory. Cohen is a first-year graduate student at MIT, and he graduated from Yale University in 2021 with a dual bachelor’s and master’s degree in mathematics. He was awarded a Goldwater Scholarship for his work and an honorable mention for the Morgan Prize — one of the highest undergraduate honors in mathematics.

Wenjie Gong
Massachusetts Institute of Technology
Physics

Wenjie Gong is interested in the intersection between quantum information and physical systems. Her goal is to develop scalable, stable and noiseless quantum devices that can push technology past the classical era. Gong is currently finishing her bachelor’s and master’s degrees at Harvard University, where she has already made significant inroads into understanding quantum phenomena in the fundamental constituents of matter. She will begin her doctorate in quantum information theory at MIT in fall 2022.

Jonah Herzog-Arbeitman
Princeton University
Physics

Jonah Herzog-Arbeitman is a condensed matter physicist working toward the discovery of new states of matter and the development of quantum materials. He hopes to tackle high-temperature superconductivity — the challenge of keeping superconductors stable at anything other than extreme cold temperatures. Herzog-Arbeitman studied physics, math and poetry as an undergraduate at Princeton University. Now a first-year graduate student at Princeton University, he is active in mentorship programs that demystify academia and the path to a career in research.

David Li 
Stanford University
Bioengineering

David Li aims to develop transformative technologies that enable new biological insights, approaches and therapies. Throughout his undergraduate career at MIT, Li worked on tools for gene editing, directed evolution and COVID-19 diagnostics. Li will spend time abroad in the U.K. as a Marshall Scholar, studying the structure of amyloid filaments at the MRC Lab of Molecular Biology through Cambridge University before pursuing a doctorate in bioengineering at Stanford University. He received a bachelor’s degree in electrical engineering and computer science from MIT in 2022.

Daniel Longenecker
Princeton University
Physics

Daniel Longenecker studies scattering amplitudes in quantum field theory and string theory at Princeton University, where he is a first-year graduate student. His goal is to contribute to the reformulation of quantum field theory by discovering new principles and mathematical structures. During his time as an undergraduate at Cornell University, where he received his bachelor’s in physics and physics education in 2021, Longenecker discovered a new connection between string theory and mathematical linguistics.

Scott Barrow Moroch
Massachusetts Institute of Technology
Physics

Scott Moroch is an experimental physicist pursuing research at the intersection of atomic, nuclear and particle physics. Using tabletop experiments, Moroch hopes to shed new light on the standard model of particle physics. He is currently a graduate student at MIT and received his undergraduate degree in physics from the University of Maryland in 2021. 

Vivek Nair
University of California, Berkeley
Computer Science

Vivek Nair develops cutting-edge cryptographic techniques to defend digital infrastructure against sophisticated cyberthreats. Currently a graduate student at the University of California, Berkeley and a researcher at Cornell’s Initiative for Cryptocurrencies and Contracts, Nair is also the founder of Multifactor.com and holds multiple patents for secure user authentication technologies. He was the youngest-ever recipient of bachelor’s and master’s degrees in computer science at the University of Illinois Urbana-Champaign.

Syamantak Payra
Stanford University
Engineering

Syamantak Payra is a scientist and engineer who is passionate about creating new biomedical devices to solve unmet health care needs. A senior at MIT, Payra has created digital fibers for electronic garments that can assist in diagnosing illnesses and has contributed to next-generation space suit prototypes that could better protect astronauts on spacewalks, among many other projects. He will begin his doctorate at Stanford University in fall 2022.

Shuvom Sadhuka
Massachusetts Institute of Technology
Computational Biology

Shuvom Sadhuka wants to apply mathematical algorithmic principles to the biological sciences to help create more efficient, private and robust tools for analyzing biological — especially genomic — data. In particular, he hopes to leverage ideas from algorithmic privacy, machine learning and data structures to create safe and efficient methods to accelerate biomedical research. He will receive his bachelor’s degree in computer science and statistics in spring 2022 from Harvard University and plans to pursue a graduate degree in computer science at MIT.

Emily Trimm
Stanford University
Biophysics, Medicine

An MD-PhD student in biophysics at Stanford University, Emily Trimm is interested in combining genomics with innovative biophysical techniques to address some of the biggest unanswered questions in human disease. Her current research uses multiomic data from high-altitude species, such as guinea pigs, alpine ibex and snow leopards, to study how the cells lining veins and arteries respond to physical force. She received her bachelor’s degree in physics and biophysics from the University of Pennsylvania in 2018.

Anonymous
Massachusetts Institute of Technology
Physics

About the Hertz Foundation

The Fannie and John Hertz Foundation identifies the nation’s most promising innovators in science and technology and empowers them to pursue solutions to our toughest challenges. Launched in 1963, the Hertz Fellowship is the most prestigious fellowship program in the U.S., fueling more than 1,200 leaders, disruptors and creators who apply their remarkable talents where they’re needed most — from our national security to the future of health care. Hertz Fellows hold 3,000+ patents, have founded 375+ companies, and have received 200+ major national and international awards, including two Nobel Prizes, eight Breakthrough Prizes, the National Medal of Technology, the Fields Medal and the Turing Award. Learn more at HertzFoundation.org.


Read More

Continue Reading

Government

US sees spike in Paxlovid usage as Merck’s molnupiravir and AstraZeneca’s Evusheld are slower off the shelf

New data from HHS shows that more than 162,000 courses of Pfizer’s Covid-19 antiviral Paxlovid were administered across the US over the past week, continuing…

Published

on

New data from HHS shows that more than 162,000 courses of Pfizer’s Covid-19 antiviral Paxlovid were administered across the US over the past week, continuing a streak of increased usage of the pill, and signaling not only rising case numbers but more awareness of how to access it.

In comparison to this week, about 670,000 courses of the Pfizer pill have been administered across the first five months since Paxlovid has been on the U.S. market, averaging about 33,000 courses administered per week in that time.

Signs for such a spike in usage were evident earlier this month as in a call with reporters senior HHS officials credited the surge in the use of Paxlovid to their outreach, and through the Biden administration’s Test to Treat initiative, which allows for use of Paxlovid with a positive test at participating pharmacies.

“We have seen more than a 315% increase in Paxlovid use over the past four weeks. In the first week of May, nearly 115,000 courses were dispensed,” an official said at the time.

Meanwhile, outside of Paxlovid, few other treatment options are really in wide use.

Merck’s molnupiravir, known commercially as Lagevrio, has struggled to make its way out of the inventory closet, according to the latest numbers posted by HHS. Only about 20,000 courses of the Merck pill were used in the past week, and only about 13% of the total US inventory of molnupiravir has been used to date. That compares with about 35% of overall usage of Paxlovid courses ordered by states so far, and the bulk of those orders have come within the last several months.

But for AstraZeneca’s Evusheld, which is a monoclonal antibody that’s supposed to be used ahead of molnupiravir if both are on hand, only about 16,000 courses were administered in the past week. But about 38% of all Evusheld ordered by states has been administered so far, according to the latest HHS numbers.

Meanwhile, HHS has become less and less transparent with its data and information on its distribution of Covid-19 therapeutics.

After the Trump administration, and the beginning of the Biden administration allowed for the public posting of weekly calls between HHS and states on Covid-19 therapeutic distribution, those calls have since been made private and the prior recordings have been deleted from the ASPR website.

In addition, each week’s therapeutic administration numbers have to be tallied independently because HHS now deletes the previous week’s numbers.

Read More

Continue Reading

Trending